Shots:

• Censa to receive $10M in cash and up to 850-000 shares of PTC’s common stock as up front- $217.5M as development and regulatory milestones for two advanced programs along with PR voucher- including $30M post completion of enrollment in P-III study of CNSA-001 for PKU
• PTC will pay $109M for each additional indication of CNSA-001- commercial milestones of up to $160M along with a contingent value payment. The transaction was approved by the Boards of both the companies and is expected to be completed in Q2’20
• CNSA-001 is an oral formulation of synthetic sepiapterin- a precursor to intracellular BH4 and has met its 1EPs & 2EPs of P-II study in Dec’2019. The company is compelling P-III ready asset t addressing the unmet need in PKU

Click here ­to­ read full press release/ article | Ref: PTC Therapeutics | Image: Npkua